Acadian Asset Management LLC Sells 25,758 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX)

Acadian Asset Management LLC cut its stake in shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) by 9.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 256,655 shares of the company’s stock after selling 25,758 shares during the quarter. Acadian Asset Management LLC owned approximately 1.00% of Leap Therapeutics worth $501,000 at the end of the most recent reporting period.

Separately, Vanguard Group Inc. increased its stake in shares of Leap Therapeutics by 111.7% in the first quarter. Vanguard Group Inc. now owns 867,708 shares of the company’s stock worth $2,308,000 after purchasing an additional 457,904 shares in the last quarter. 30.46% of the stock is owned by institutional investors.

Leap Therapeutics Stock Performance

Shares of NASDAQ LPTX opened at $2.88 on Thursday. The company has a market cap of $73.73 million, a P/E ratio of -1.21 and a beta of 0.27. Leap Therapeutics, Inc. has a 52-week low of $1.24 and a 52-week high of $5.00. The firm’s fifty day moving average is $2.50 and its two-hundred day moving average is $2.51.

Leap Therapeutics (NASDAQ:LPTX) last issued its earnings results on Monday, August 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.10). As a group, analysts forecast that Leap Therapeutics, Inc. will post -1.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on LPTX shares. HC Wainwright restated a “buy” rating and set a $5.50 target price on shares of Leap Therapeutics in a research note on Tuesday, August 13th. Rodman & Renshaw initiated coverage on Leap Therapeutics in a research note on Friday, June 28th. They issued a “buy” rating and a $8.00 price objective for the company. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Leap Therapeutics has a consensus rating of “Buy” and a consensus price target of $10.40.

Leap Therapeutics Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.